Targacept Announces Designation Of Lead Compound In Smoking Cessation Program
Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced the designation of a lead compound in its smoking cessation program, triggering a $500,000 milestone payment under its alliance agreement with GlaxoSmithKline (GSK).
More: continued here
Filed under: Smoking / Quit Smoking on May 15th, 2008